Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000647330 | SCV000769120 | likely benign | Familial hemophagocytic lymphohistiocytosis 5 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV000647330 | SCV002814037 | uncertain significance | Familial hemophagocytic lymphohistiocytosis 5 | 2021-11-01 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526731 | SCV005039869 | uncertain significance | not specified | 2024-03-18 | criteria provided, single submitter | clinical testing | Variant summary: FANCC c.1393C>T (p.Gln465X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251264 control chromosomes. c.1393C>T has been reported in the literature in multiple individuals affected with Fanconi Anemia Group C. These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |